Losses and delayed profitability due to continued R&D investment
First written in FY2021. 12 of 18 entries say "Mitigated", first in FY2023-Q1. Latest entry: 2026-08-10.
The whole theme swung hardest in 2023: 4 of 6 companies on the "Worse" side.
5 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「Operating loss was ¥326.213 million (operating loss of ¥445.689 million in the previous fiscal year), ordinary loss was ¥305.758 million (ordinary loss of ¥443.547 million), and net loss was ¥357.147 million (net loss of ¥445.768 million).」
Although the company continued to record losses, operating, ordinary and net losses all narrowed from the previous fiscal year. - FY2026-H1MitigatedAnnual report
「Operating loss was ¥169.569 million (operating loss of ¥295.468 million in the same period of the previous year), ordinary loss was ¥162.726 million (ordinary loss of ¥302.820 million), and interim net loss was ¥163.834 million (interim net loss of ¥303.927 million).」
Although operating, ordinary and net losses all narrowed from the same period of the previous year, the company continued to record losses. - FY2025MitigatedAnnual report
「As a result, revenue for the fiscal year was ¥1,308.870 million, up 4.9% from the previous fiscal year. Operating loss was ¥445.689 million (operating loss of ¥604.014 million in the previous fiscal year), ordinary loss was ¥443.547 million (ordinary loss of ¥600.972 million), and net loss was ¥445.768 million (net loss of ¥642.627 million).」
Although operating, ordinary and net losses all narrowed from the previous fiscal year, the operating loss, accumulated losses and negative operating cash flow continued. - FY2025-H1WorsenedAnnual report
「As a result, sales for the six-month period were ¥559,360 thousand, down 12.4% year on year. Selling, general and administrative expenses continued to exceed gross profit as sales channels were still being developed following a change in the sales policy for the visual information device business. Operating loss was ¥295,468 thousand, compared with an operating loss of ¥243,330 thousand in the same period of the previous year; ordinary loss was ¥302,820 thousand, compared with ordinary loss of ¥248,611 thousand; and interim net loss was ¥303,927 thousand, compared with interim net loss of ¥250,801 thousand.」
Selling, general and administrative expenses continued to exceed gross profit while sales channels were being developed following a change in sales policy, and operating, ordinary and net losses all increased from the same period of the previous year. - FY2024WorsenedAnnual report
「However, as a result, the company also recorded an operating loss in the fiscal year ending March 2024 and had accumulated losses, while operating cash flow was also negative.」
While continuing to invest in research and development, the company continued to post an operating loss and accumulated losses, and operating cash flow remained negative, in the fiscal year ending March 2024. Operating loss increased from ¥556.770 million in the previous fiscal year to ¥604.014 million. - FY2024-Q3MitigatedAnnual report
「As a result, revenue for the cumulative third quarter was ¥904.762 million, up 31.5% year on year. As the laser eyewear business was still in the process of being launched, selling, general and administrative expenses continued to exceed gross profit. Operating loss was ¥375.850 million (operating loss of ¥444.589 million in the same period of the previous year), ordinary loss was ¥366.431 million (ordinary loss of ¥442.134 million), and quarterly net loss was ¥369.703 million (quarterly net loss of ¥444.801 million).」
Although losses associated with the business launch and research and development continued, revenue increased 31.5% year on year, and operating, ordinary and net losses all narrowed from the same period of the previous year. - FY2024-Q2MitigatedAnnual report
「As a result, revenue for the cumulative second quarter was ¥638.195 million, up 33.7% year on year. As the laser eyewear business was still in the process of being launched, selling, general and administrative expenses continued to exceed gross profit. Operating loss was ¥243.330 million (operating loss of ¥288.349 million in the same period of the previous year), ordinary loss was ¥248.611 million (ordinary loss of ¥267.915 million), and quarterly net loss was ¥250.801 million (quarterly net loss of ¥269.754 million).」
Although losses associated with the business launch and research and development continued, revenue increased and operating, ordinary and net losses all narrowed from the same period of the previous year. - FY2024-Q1MitigatedAnnual report
「As a result, revenue for the cumulative first quarter was ¥255.932 million, up 19.9% year on year. As the laser eyewear business was still in the process of being launched, selling, general and administrative expenses continued to exceed gross profit. Operating loss was ¥126.946 million (operating loss of ¥163.415 million in the same period of the previous year), ordinary loss was ¥130.015 million (ordinary loss of ¥148.593 million), and quarterly net loss was ¥131.007 million (quarterly net loss of ¥149.558 million).」
Although losses associated with the business launch continued, operating, ordinary and quarterly net losses all narrowed from the same period of the previous year. - FY2023MitigatedAnnual report
「Operating loss was ¥556.770 million (¥931.547 million in the previous fiscal year), ordinary loss was ¥546.884 million (¥893.536 million), and net loss was ¥550.379 million (¥880.967 million).」
Although losses associated with research and development and business launch activities, as well as negative operating cash flow, continued, operating, ordinary and net losses all narrowed from the previous fiscal year. - FY2023-Q3WorsenedAnnual report
「Selling, general and administrative expenses exceeded gross profit due to development expenses for 3 new products for the laser eyewear business and other factors, resulting in an operating loss of ¥444.589 million, compared with an operating loss of ¥380.569 million in the same period of the previous year, an ordinary loss of ¥442.134 million, compared with an ordinary loss of ¥378.514 million, and a quarterly net loss of ¥444.801 million, compared with a quarterly net loss of ¥363.594 million.」
Selling, general and administrative expenses exceeded gross profit due to development expenses for new laser eyewear products and other factors, and operating, ordinary and net losses all increased from the same period of the previous year. - FY2023-Q2WorsenedAnnual report
「As the laser eyewear business was still being launched, selling, general and administrative expenses continued to exceed gross profit, resulting in an operating loss of ¥288.349 million, compared with an operating loss of ¥276.695 million in the same period of the previous year, an ordinary loss of ¥267.915 million, compared with an ordinary loss of ¥276.677 million, and a quarterly net loss of ¥269.754 million, compared with a quarterly net loss of ¥260.740 million.」
Selling, general and administrative expenses continued to exceed gross profit as the laser eyewear business remained in the launch phase, while operating loss and quarterly net loss increased from the same period of the previous year. - FY2023-Q1MitigatedAnnual report
「As a result, net sales for the cumulative first-quarter period were ¥213.438 million, down 4.3% year on year. As the laser eyewear business was still being launched, selling, general and administrative expenses continued to exceed net sales, resulting in an operating loss of ¥163.415 million, compared with an operating loss of ¥200.691 million in the same period of the previous year, an ordinary loss of ¥148.593 million, compared with an ordinary loss of ¥202.745 million, and a quarterly net loss of ¥149.558 million, compared with a quarterly net loss of ¥206.244 million.」
Operating loss, ordinary loss and quarterly net loss all narrowed from the same period of the previous year. However, selling, general and administrative expenses continued to exceed net sales as the laser eyewear business remained in the launch phase. - FY2022WorsenedAnnual report
「We recorded operating losses in the fiscal years ended March 2021 and March 2022, carried accumulated losses, and had negative operating cash flow.」
Operating losses, accumulated losses and negative operating cash flow associated with continued research and development investment were reported for 2 consecutive fiscal years, indicating that achieving profitability may take time. - FY2021First statedAnnual report
「We recorded operating losses in the fiscal years ended March 2020 and March 2021, carried accumulated losses, and had negative operating cash flow.」
It identifies delayed profitability due to insufficient returns on investment or higher costs as a risk, following the recognition of research and development expenses ahead of revenue and the resulting operating losses, accumulated losses and negative operating cash flow.